
ãšã€ãºããã³ãããŸã§ - åäœå¶éåã®æŽå²
Unbekoming andMichael Wallach
May 29, 2026

ããŠã€ã«ã¹åŠæ³ãã®ç£ç£ã§ãããã€ã±ã«ã»ãŠã©ã©ãã¯ã¯ã1980幎代ã®ãšã€ãºå察éåã®äžå¿äººç©ã§ãããããã«ã»ãã¯ã¹ç é¢ã®è±åœåã®ãšã€ãºç æ£ã§åããHIVæ€æ»ã«é¢ããå士ç ç©¶ãå®äºããåŸã«2020幎ã®ããã¯ããŠã³ã«å ¬ç¶ãšå察ããæåæã®äººç©ã®äžäººã§ãããSARS-CoV-2ã²ãã ãé©åã«é åæ±ºå®ããããšããäž»åŒµã®æ€åãæ±ããæåã®ç§åŠè«æãå ±åå·çããã±ãã³ã»ã³ãŒãããå士ã«ãã®æ³šç®ãã¹ãã€ã³ã¿ãã¥ãŒãè¡ã£ããç§ã¯ããã®ã€ã³ã¿ãã¥ãŒãLies are Unbekomingã§å ¬éã§ããæ©äŒãå¬ããæãã以äžã¯ãç æ£å éšããèªããã40幎éã®è»è·¡ã§ãããå æ¬çãªå®æ¥œæ»ãããã³ã«ãšããŠæ©èœãããäºåŸæ²èгè«ããåç §æšæºããªãã£ãæäœæ€æ»ãã ããã®ãšã€ãºè«®åå§å¡äŒãšCDCã®æ¥ãã®ãã¡ãŒãžã³ã³ãããŒã«ãããŒã¹ã°ã«ãŒãããã¥ãŒã¹ããŒã°ãæ¿ããæŽŸé¥åè£ããããŠãããããã¹ãŠãçµã³ã€ããå ±éã®ç³žã¯ãæ°åã³ãããŠã€ã«ã¹ææçïŒCOVID-19ïŒã§ãããã®æŽå²ãç¥ããªã人ã«ãšã£ãŠãã±ãã³ã®èšŒèšã¯æãåãããããå ¥éæžã®äžã€ãšèšããã§ãããã
以äžã¯ã1980幎代以éããšã€ãºã«é¢ããéèŠãªåäœå¶æŽ»åå®¶ãšããŠæŽ»èºãã2020幎ã®ããã¯ããŠã³ã«å ¬ç¶ãšå察ã®å£°ãäžããæåæã®äººç©ã®äžäººã§ãããã±ãã³ã»ã³ãŒãããå士ãžã®ã€ã³ã¿ãã¥ãŒã§ããã³ãŒãããå士ã¯ããSARS-CoV-2ãã®ã²ãã é åãé©åã«è§£èªãããPCRæ€æ»ã§æ€åºã§ãããšããäž»åŒµã®æ€åãæ±ããæåã®ç§åŠè«æãå ±åçºè¡šããŸããã
ã±ãã³ã¯ãçŸåšç¡æã§å šç·šèŠèŽå¯èœãªããŠã€ã«ã¹åŠæ³ã第5話ããšã€ãºïŒèŽåœçãªæ¬ºçãã§ã€ã³ã¿ãã¥ãŒããæ°å€ãã®ååºããç§åŠè ã®äžäººã§ãããã®ãšããœãŒãã¯ããšã€ãºå察éåãšããHIVãããšã€ãºã®åå ã§ãããšããäž»åŒµã®æ ¹åºã«ããç§åŠçè©æ¬ºãæãããæ°å°ãªãããã¥ã¡ã³ã¿ãªãŒã®äžã€ã§ãããã®æŽå²ããåç¥ãªãæ¹ã®ããã«èª¬æãããšãããã¯30幎è¿ããé èœãããŠããé©ãã¹ãç©èªã§ãããç§ã®ç§åŠãå»åŠãæ¿æ²»ãæåã«å¯Ÿããçè§£ãæ ¹åºããèŠããã®ã§ããã
âãã€ã±ã«ã»ãŠã©ã©ãã¯ïŒããŠã€ã«ã¹åŠæ³ãç£ç£ïŒ
1. ã±ãã³ããããåå ããã ãæ¬åœã«ããããšãããããŸãããšã€ãºãšã®é¢ããã«ã€ããŠæããŠããã ããŸããïŒãšã€ãºã«ã€ããŠå ¬ã«çºèšããããã«ãªã£ããã£ããã¯äœã§ããïŒ
ç§ããšã€ãºãšåããŠé¢ãã£ãã®ã¯ã1982幎ã«ã¬ãºãã¢ã³ãã²ã€ããã€ã»ã¯ã·ã¥ã¢ã«ã®äººã ã®ããã®ãã«ãã©ã€ã³ã§ãã©ã³ãã£ã¢ãããŠããæã§ãããçç¶ã®ãªãã²ã€ç·æ§ããæ¬äººã®ç¥ããªããã¡ã«HTLV-IIIïŒHIVã®å身ãšãªãç¥èªïŒæäœã®æ€æ»ãå¯ãã«åããŠãããšããå ±åã倿°ãããŸãããåœæãäž»æµã¡ãã£ã¢ãå»çæ©é¢ã¯ã²ã€ç·æ§ãã容çè ããææè ããç 人ããšããŠæ±ã£ãŠããŸãããç§ã¯ãè±åœåã®ãšã€ãºæ¯æŽå£äœãèšç«ãããå ¬ééäŒã«åºåžããŸããã
1983幎ã«çè·åž«ã®é€æèª²çšãå§ãããšããç§ããšã€ãºã«ã€ããŠåŠã³ãŸããã1986å¹Žã«æ£çè·åž«ïŒRNïŒã®è³æ ŒãååŸããéãHTLVIIIæäœæ€æ»ã®çµæãåŸ ã£ãŠããã²ã€ã®ç·æ§æ£è ãããå°éã¹ã¿ãããã©ã®ããã«åœŒãéé¢ããããšãã話ãèããŸããã1986幎ãç§ã®ç æ£ã«åããŠãšã€ãºæ£è ãå ¥é¢ããŠãããšããã¹ã¿ããã¯é²è·æã®ãããªå®å šé²è·æãççšããŠããŸããã
1980幎代ããšã€ãºåéã¯å°éçã«ãç§åŠçã«ã倧ããªèª²é¡ãæ±ããŠããŸããã1987幎ãç§ã¯ãã³ãã³ã®ããã«ã»ãã¯ã¹ç é¢ã«éèšãããè±åœåã®ãšã€ãºç æ£ã§æ£çè·åž«ãšããŠåãå§ããŸãããæ£è ã¯è€æ°ã®çŸæ£ãæ±ããé節ãªç¶æ ã§å ¥é¢ããããšãå€ãã£ãã®ã§ããå€ãã®æ£è ãäºå®äžã®ã宿¥œæ»ããããã³ã«ã«åºã¥ããŠæ²»çãåããäºåŸã«å¯Ÿããæ²èŠ³çãªèŠæ¹ãèå»¶ããŠããã®ãç®ã®åœããã«ããŸããã
ãã®è²Žéãªçµéšããã£ãããšãªããç§ã¯1990幎代åã°ãŸã§èšåºå»ãšããŠãã£ãªã¢ãç©ã¿ãæ§ã ãªèšåºããã³åŠè¡çãªãªãŒããŒã·ããã®åœ¹å²ãæ ããŸããããã®éãHIVæäœæ€æ»ãå«ããšã€ãºé¢é£æè¡ã®ç ç©¶ã«ãæºãããŸãããå士課çšã®ç ç©¶ã§ã¯ãç°è«ãå±ãããšã€ãºã«é¢ããèšèª¬ãªã©ããšã€ãºç§åŠã«é¢ããæ§ã ãªèŠç¹ãåãäžãããããã¯ãã¹ãŠãã®åŸã®ç§ã®å°éçãªæé·ã«å€§ããè²¢ç®ããŸããã
2. ãšã€ãºãšä»æ¥ã®ã°ããŒãã«ãã«ã¹ã«é¢ãã察話ã«ã¯ã©ã®ãããªé¢é£æ§ããããŸããïŒ
補è¬äŒæ¥ã«ãããã°ããŒãã«ãã«ã¹å¯Ÿè©±ãã¯ãååœã®ä¿å¥æ©é¢ïŒäŸïŒCDSCïŒè±åœå ¬è¡è¡çç ç©¶æïŒã®æ¯æŽãåããŠã1984幎4æã«ãšã€ãºãã¬ãããŠã€ã«ã¹ã«ãã£ãŠåŒãèµ·ãããããšåããŠäž»åŒµãããæãããå»åŠçæ€æ»ã𿝿§ã®ãããšã€ãºæ²»çè¬ãçã¿åºããã
ãšã€ãºã¯ã1981幎ã«åããŠå ±åããããããŸããŸãªç ç¶ã®éåäœã§ããã1984幎ã®ã¬ãããŠã€ã«ã¹ã«ããåå 説ããã以åã«ååšããŠããããšã€ãºã«é¢é£ããå€ãã®ç ç¶ã¯ã人éã®è¡åã«ããææã«ãã£ãŠåŒãèµ·ããããã
ã²ã€ããã€ã»ã¯ã·ã£ã«ã®ç·æ§ã¯ãè¬ç©ä¹±çšãæ§ç乱亀ïŒç°æ§æè ãšäœãå€ãããªãïŒãã»ã³ã»ãŒã·ã§ãã«ã«å ±éãããããã«ç€ŸäŒçã«æšçã«ãããç·æ§åå£«ã®æ§è¡çºã«å¯Ÿãã瀟äŒçã»ç¥åŠçãªéé£ãšçžãŸã£ãŠãæ¿ããææªãåããããããã瀟äŒçãªæ¥èŸ±ãžãšã€ãªãã£ãã
1984幎以éããšã€ãºã¯ããŠã€ã«ã¹ãã«ãã£ãŠåŒãèµ·ãããããšããæ£çµ±çãªèãæ¹ãåºããããããã«ãã£ãŠå²ããå»çæ€æ»ãæå®³ãªè¬å€ã®åžå Žãæ¡å€§ããã
ã»ãªã¢ã»ãã¡ãŒããŒïŒãã¥ãŒãšãŒã¯ïŒããžã§ãŒã³ã»ã·ã§ã³ãã³ïŒã€ã®ãªã¹ïŒãšãã£ããžã£ãŒããªã¹ãããã ã»ãã£ãã§ã«ãã£ãã³ãïŒââãã¥ãŒãšãŒã¯ïŒããã€ã±ã«ã»ãšã«ããŒïŒãã¥ãŒãšãŒã¯ïŒãšãã£ãã³ãã¥ããã£ã®ãã©ã³ãã£ã¢ããããŠãžã§ã³ã»ããŒãªããã§ã³ïŒã¢ã¡ãªã«ïŒãã€ã¢ã³ã»ã€ã³ã°ïŒã«ããïŒããžã§ãã£ã»ãŠã§ã«ãºããã¥ãŒã»ã¯ãªã¹ãã£ïŒåŸè 2åã¯ã€ã®ãªã¹ã®ã³ã³ãã£ãã¥ã¢ã èªïŒãšãã£ãã²ã€ã³ãã¥ããã£ã®å£°ã¯ããã®æ£çµ±çãªèŠè§£ã«æ¹å€çã«å察ããã
ãããã®å£°ã¯ããšã€ãºã®åå ãã¬ãããŠã€ã«ã¹ã§ãããšããèãæ¹ã«ç°è°ãå±ãããŠã€ã«ã¹åŠè ããŒã¿ãŒã»ãã¥ãŒã¹ããŒã°ïŒç±³åœïŒãçååŠè ãã€ãããã»ã©ã¹ããã¯ïŒç±³åœïŒããããŠãHIVãã®ãŠã€ã«ã¹åŠã«ç°è°ãå±ããæ çç©ç©çåŠè ãšã¬ãã»ãããããã¹ïŒãšã¬ãªããã¹ãçããèªç§°ãããŒã¹ã»ã°ã«ãŒãããšåŒã°ããçç©å»åŠç ç©¶è ãã¡ã®ç ç©¶ã宣äŒããã
1991幎ãããŒã¿ãŒã»ãã¥ãŒã¹ããŒã°ã®ç ç©¶ãäžå¿ã«ãç±³åœãæ ç¹ãšããã°ã«ãŒãããšã€ãºåèïŒRethinking AIDSïŒããçµæãããããã®åŸãã«ããã®ããããã»ã¯ããŠããªãŒããŒãåããããšã€ãºåèã¯ããšã€ãºå察掟ã®å¹ åºãé£åäœã§ããïŒç©è°ãéžããããããŒã¹ã»ã°ã«ãŒãã¯é€å€ãããïŒãã¢ããªã«å²å®¶ã®ãã£ãŒã«ãºã»ã¬ãŒã·ã§ã¯ã¿ãŒïŒç±³åœïŒã®ãããªéç§åŠè ããã»ãªã¢ã»ãã¡ãŒããŒããžã§ãŒã³ã»ã·ã§ã³ãã³ãšãã£ããžã£ãŒããªã¹ããå«ãŸããŠããã
ãšã€ãºç°è«è ãã¡ã¯ãäž»æµç§åŠã«å¯Ÿããæç®æ¹å€ãäž»ã«çºè¡šãããããã¯ãæ¯èŒçè³éãæœ€æ²¢ãªæ£çµ±æŽŸã®ç§åŠçææã«å¯Ÿæããããã®å®éšç ç©¶ããã°ã©ã ã宿œããããã®ç 究宀ã®ãªãœãŒã¹ãå°éç¥èãéãããŠããããã§ãããäž»æµã®åŠè¡èªã¯ãHIVãå€ç«ãããŠã€ã«ã¹ã§ããããšã€ãºãåŒãèµ·ãããšããæ£çµ±æŽŸã«ç°è°ãå±ããèè ã«å¯ŸããŠã¯ãã»ãŒå®å šã«éæžãéãããŠãããããããéçªå¶ãããã»ã©å³æ Œã§ã¯ãªãåŠè¡èªããããæ£çµ±æŽŸã«ç°è°ãå±ããè«æãæ²èŒããããäŸãã°ã1993幎ã«BioTechnologyèªã«æ²èŒãããPapadopulos-Eleopulosãã®è«æããŠã§ã¹ã¿ã³ããããéœæ§ã¯HIVææã®èšŒæãïŒããªã©ã§ãããéäž»æµã®åŠè¡èªã¯ããšã€ãºç°è«è ãã¡ã«éæžãéããŠããã
ç·ããŠããšã€ãºå察掟ã¯ãHIVãã®ååšãããã£ãŠäºãã«å¯Ÿç«ãã2ã€ã®ã°ã«ãŒãã«åããããã®åŸïŒæ¿ããïŒå éšè«äºãç¹°ãåºããããããã®ãäºå±€æ§é ãã¯ãSARS-CoV-2ãã§ãã¯ããã«å€§èŠæš¡ã«åçŸããããå°æ°ã®å察掟ç§åŠè ã¯ããããããSARS-CoV-2ãã®åé¢ç§åŠã«å察ãããããŠã€ã«ã¹åé¢ç§åŠã«ç°è°ãå±ããããã«å¿ èŠãªè³éãå®éšå®€ã®å°éç¥èãžã®ã¢ã¯ã»ã¹ãéãããŠãããäžæ¹ãæ¯èŒç倿°ã®ç§åŠè ã¯ãSARS-CoV-2ãã®ãŠã€ã«ã¹åé¢ç§åŠãåãå ¥ãã€ã€ãé¢é£ãããã¯ã¯ãã³ãããã®ä»ã®å»çã»å»è¬åä»å ¥ã«æ¿ããå察ããã
ãã°ããŒãã«ãã«ã¹å¯Ÿè©±ãã¯ãæŽå²çã«ããšã€ãºãããCOVIDãã§åçŸããŠãããè³æºè±å¯ãªäž»æµç§åŠçããäŒæ¥å©çãååœã®ä¿å¥æ©é¢ïŒçŸç ç£èŠç®¡çã»ã³ã¿ãŒïŒã®æ¯æŽãæåãåããŠãæ°ããªããŠã€ã«ã¹æ§ãçå矀ãæå±ãããããã®åŸãæ¯èŒçè³æºã®ä¹ããç§åŠè ãšãã®æ¯æè ã«ãã£ãŠéå®éšçã«å蚌ãããã
3. ææçãšãªã¹ã¯èšç®ã«ã€ããŠãç§ãã¡ã¯ããç®ã«ãããè³ã«ãããããŸããèªåèªèº«ãåšå²ã®äººã ã®å¥åº·ã®ããã«ãæ€æ»ãåãããã¯ã¯ãã³æ¥çš®ãåãããããããã倧ããªãã¬ãã·ã£ãŒãããã£ãŠããããã«æããŸããããã¥ã¡ã³ã¿ãªãŒã®äžã§ããªã¹ã¯èšç®ã«é¢ãã察話ã«ã€ããŠãããªãã¯éåžžã«éåŒã«èªã£ãŠããŸãããããã«ã€ããŠãããå°ã詳ãã説æããŠããã ããŸããïŒ
äž»æµæŽŸïŒãHIVãïŒã®ãšã€ãºãªã¹ã¯èšç®ã¯ãããããç«åŠçã°ã«ãŒããããã¡ã€ã«ã«äŸåããŠãããããã¯æ§ã ãªããããèªå·±ç³åã«ãããªã¹ã¯è¡åã«åºã¥ããŠãããäŸãã°ã1980幎代ã«ã¯ãç¡é²åãªæ§è¡çºïŒäž»ã«èéæ§äº€ïŒãéèæ³šå°ãäžååãªã¹ã¯ãªãŒãã³ã°ãåããè¡æ¶²è£œå€ã®æäžãªã©ããªã¹ã¯è¡åãšããŠæããããŠãããäž»æµæŽŸã®ãšã€ãºïŒãŠã€ã«ã¹ä»®èª¬ã¯ãããŠã€ã«ã¹ãããšã€ãºãåŒãèµ·ããïŒäººã ãæ§çã«ããããã¯ãã®ä»ã®æ¹æ³ã§èªåã®äœã«å¯ŸããŠäœãããããšããæ±ºå®ã®çµæã§ã¯ãªãïŒãšä»®å®ããããšã§ãå人ã®è¡åéžæãåé¿ããã
ãšã¬ãã»ãããããã¹ïŒãšã¬ãªããã¹ã¯ã1988幎ã«å»åŠèªã Medical Hypothesesãã«æ²èŒãããè«æããšã€ãºã®åè©äŸ¡ â å±éºå åã«ãã£ãŠèªçºãããé žåãäž»ãªåå ãïŒãã®äžã§ããšã€ãº/ãŠã€ã«ã¹ä»®èª¬ãæ¹å€ãã粟液ãå ç«æå¶ãåŒãèµ·ããé žåå€ã§ããããšã瀺ãããåœŒå¥³ã¯æ¬¡ã®ããã«è¿°ã¹ãŠããããè£ã¯åãéå±€æå¹³äžç®ã§èŠãããŠããããã粟液ãè¡ç®¡å±€ã«æœ°çã圢æãããæµžæœ€ãããããããšã¯ãŸããããŸãããäžæ¹ãçŽè žå ã®ç²Ÿæ¶²ã¯åå±€ã®çްèã«ãã£ãŠè¡ç®¡ããªã³ã管ããéãŠãããŠãããããèéæ§äº€äžã«å®¹æã«æµžæœ€ããæœ°çã圢æããŸãããæ¯èŒçç¡åã®éèªã«æ²èŒããããã®éèŠãªææã¯ãèéæ§äº€ã«äŒŽããªã¹ã¯ãèšç®ããŠãã人ã ïŒç¹ã«ã²ã€ç·æ§ïŒã«ãšã£ãŠéåžžã«å€§ããªæå³ãæã£ãŠããããããããã®ã¡ãã»ãŒãžã¯ã1988å¹Žåœæãã²ã€ã®ã¢ã€ãã³ãã£ãã£æ¿æ²»ã«ç²ç®ã«ãªã£ãŠããäž»æµæŽŸã«ãã£ãŠç¡èŠããããšã€ãºã®åå ã¯ãŠã€ã«ã¹ä»®èª¬ã§ãããšããèªèã«åãããŠããŸã£ãã
ä¿è·ãããŠããªãæ§è¡çºïŒäž»ã«èéæ§äº€ïŒã¯ã粟åã®æ¢ç¥ã®é žåäœçšãå ç«æå¶äœçšãç¡èŠããŠãåé¢ãããŠããªããŠã€ã«ã¹ãžã®æé²ã蚱容ãããã®ãšããŠæšå¥šãããŠããããããããã¹ïŒãšã¬ãªããã¹ã1988幎ã®è«æã§è¿°ã¹ãããšã¯äºèšçã§ãã£ãããä»ã®ãŠã€ã«ã¹ãšã¯ç°ãªããHTLV-III/LAV ['HIV'] ã¯ç¬ç«ããå®å®ããç²åãšããŠåé¢ãããããšããªãããšã匷調ããªããã°ãªããªããå®éããŠã€ã«ã¹ã®åé¢ãšã¯ã现èå¹é€ã«ããããŠã€ã«ã¹æåããŠã€ã«ã¹æäœãé転åé µçŽ ïŒRTïŒãããã³çްèèãã现èå€ç©ºéã«èœçãããŠã€ã«ã¹æ§ç²åã®äžæçãªæ€åºãæå³ãããã»ãšãã©ã®å Žåãåé¢ã¯RTæ€åºãšå矩ã§ãããã2020幎ãŸã§æ©éããããšãããã¯åŸã«ãSARS-CoV-2ãã«å¯ŸããŠå®æœãããæ€æ»äœå¶å šäœãèŠçŽããŠãããå®å®ããç²åã¯ç¹å®ãããããŠã€ã«ã¹ç±æ¥ãšãããéºäŒåæçã®ã¿ãç¹å®ãããã
4. ããªãã¯ãšã€ãºæ€æ»ã®åŠ¥åœæ§ããããŠæ€æ»ã瀟äŒãå¥åº·ã«åãŒã圱é¿ã«ã€ããŠãããçš®ã®å°éå®¶ã«ãªã£ãããã§ãããããã«ã€ããŠãèããããã ããŸããïŒ
ç§ã¯ãã©ã³ãã£ã¢æŽ»åãä»äºããããŠç ç©¶ãéããŠãHIVæ€æ»ããããã圱é¿ã宿ããããã«ãªããŸãããäŸãã°ã1980幎代åé ããšã€ãºæ€æ»ã¯å·®ãè¿«ã£ãæ»ãšæ·±å»ãªç€ŸäŒçåèŠã飿³ãããããã倧ããªææãåŒãèµ·ãããŸãããã²ã€ã®ç·æ§ã¯å ¬ç¶ãšèŸ±ããããæ¥ãããããããšã€ãºã®åå ã ãšéé£ãããã®ã§ãã
1980幎代以éãæ€æ»ã¯äžè¬çã«ãªããããããçŸè±¡ã«å¯Ÿããæ€æ»ãæ¡å€§ããŠãããHIVæ€æ»ã¯ã²ã€ç·æ§ã®éã§ããŠã€ã«ã¹çããªæåãçã¿åºããæé²åŸäºé²ïŒPEPïŒããã³æé²åäºé²ïŒPrEPïŒã®æ®åã«ã€ãªãã£ãïŒããã¯ç°æ§æè ã®å¥³æ§ãåŠåš äºé²ã®ããã«è¬ãæçšããã®ãšé¡äŒŒããŠããïŒã
ãããã®å»è¬åã¯ããå¯äœçšãŒãããŸãã¯ãå¯äœçšéå®ãã謳ã£ãŠè²©å£²ãããŠãããããã¡ããããã¯å šãã®åã§ããã人ã ã¯ææå¿ãç œãã¡ãã»ãŒãžãã矩åæãæ¥ã®æèãšãã£ã誀ã£ãæŠå¿µãå©çšããŠãæè¬éµå®ãžãšèªå°ãããŠããã
5. 仿¥ãç§ãã¡ã¯ç æ°ã«é¢ããæ å ±ã«æº¢ãããã£ãŠããŸãããããããåéã®ç¥èããªãäžè¬ã®äººããã©ããã£ãŠãããã®æ å ±ãæŽçããã°è¯ãã®ã§ããããïŒ
ããªãããæ®éã®äººããšèšããšããç§ã¯å»åŠçã»å°éçãªç¥èãäž»æµã®ç§åŠçç¥èãã»ãšãã©ããããã¯å šãæããªããããæ®éã®äººããæããŠãããšè§£éããŸããæ¹å€çãªèŠç¹ãšæéããããæ³šææ·±ãåãçµãããšãã§ããã°ãçºä¿¡ãããæ å ±ã®äžããããããã®æ å ±ãçã¿åºãããç¶æãããåºããããéçšã«ãããåèŠãæ¢åŸæš©çãè§£ãæããããšãã§ããã§ãããã
ããã¯ãããããã代æ¿ãæ å ±æºã§ãã£ãŠããããããæ å ±æºã«ãããåããè§£æããéã«ãåæ§ã«åœãŠã¯ãŸãã
ããã¯äººã«ãã£ãŠã¯é¢åã§ç²ããããã»ã¹ã«ãªããããããªãããä»ã®äººã«ãšã£ãŠã¯ããã»ã©é£ãããªããããããªãã
人ã ã¯ãæ å ±çºä¿¡è ã®å°äœãããããæš©åšã«æããããå¥åº·ç®¡çããã¢ãŠããœãŒã·ã³ã°ãããããä¿ãããããšãå€ããã€ãŸãã身äœã®äž»æš©ã«é¢ãã責任ããããããå°éå®¶ããã®ä»ã®æš©åšè ãšããã人ã ã«å§ããŠããŸãã®ã ãäž»æµã®çŸç æ å ±çºä¿¡ã¯ã補è¬äŒæ¥ãçç©å µåšç£æ¥ãšçŽæ¥çµã³ã€ããŠããããããã¯ãçŸç ã®çºçããããã³ãããã¯ããšãã£ãææã«åºã¥ãçŸè±¡ãçã¿åºãäžã§éèŠãªåœ¹å²ãæãããŠãããäžéšã®äººã ã¯ãæ¥ã矩åæããããŠå ¬è¡ã®é¢åã§ã®æŽé²ãžã®ææãšãã£ãå¿ççã¡ã«ããºã ã«ã€ã蟌ãŸããå»çæ€æ»ãæ²»çãäºé²è¬ã®æçšããããŠããäžè¬çã«ã¯ãçµ¶ããå€åããæ§ã ãªè¬ç©çæ³ã«åŸãããä¿ãããã
6. ãšã€ãºéåãšåäœå¶æŽŸãšã€ãºéåã®æŽå²ãç¥ããªã人ã«ãç§ãã¡ãããããäœãåŠãã ãã説æããæãç°¡åãªæ¹æ³ã¯äœã§ããïŒ
人ã¯ãç¹ã«èªã泚æãã¹ãç¹ãçµéšããã°ãããããæ£çµ±çãªèãæ¹ã®èª€ããèŠæãããã«ãªããããããŸãããäŸãã°ãHIVæã¬ãããŠã€ã«ã¹è¬ïŒARVïŒãæçšããŠãã人ã¯ãTçŽ°èæ°ããå¢å ããããŠã€ã«ã¹éããæžå°ããããšèª¬æãããŸããããã®ããã¿ãŒã³ãã¯å®éã«ã¯çµéšãããªãããšããããããŸãïŒãã®ããã¿ãŒã³ãã¯æ€æ»æè¡ã®ã¢ãŒãã£ãã¡ã¯ãã§ãïŒããã®äºæ³ããããã¿ãŒã³ãçµéšãããªãå Žåã人ã ã¯å¹»æ» ããæ²»çã«åŸããªããªãå¯èœæ§ããããARV/HIVæ€æ»ã®çµéšå šäœã«å¯Ÿããæ¹å€çãªæŽå¯ã«ç®èŠãããããããŸãããããã¯ãç§èªèº«ã®ç ç©¶ã§åãäžããåéã®äžã€ã§ããHIVæ£è ã®äžã«ã¯ãèªåãããŠã€ã«ã¹ããäœçŸããŠãããšãä¿¡ããŠãããã«ãããããããARVã«å¯ŸããŠéåžžã«æ¹å€çãªäººãå€ãããŸãã
ç°è«ãå±ããç§åŠè ãã¡ã¯ãäž»æµã®ãšã€ãºç ç©¶ã«å¯Ÿæã§ããã ãã®è³éãè³æºããªããŠããç ç©¶ææãçºè¡šããåºããæ¹æ³ãå¿ ãèŠã€ãåºãããšãã§ãããç°è«ãå±ãããšã€ãºç ç©¶éåã¯ãäž»æµã®ãšã€ãºç ç©¶ã®æ£çµ±æ§ãèŠããŸã§ã«ã¯è³ã£ãŠããªããã®ã®ãç§åŠè ã ãã§ãªãéç§åŠè ã«ã圱é¿ãäžããŠãããäž»æµã®æ£çµ±æ§ãèŠãã«ã¯ãåã ã®ç°è«è ããããã¯ç°è«è ã®ã°ã«ãŒããæã€ä»¥äžã®è³éãšç ç©¶æœèšãå¿ èŠãšãªãã ããã
äž»æµããå€ããæŽ»åã«ã¯ãå©ç¹ã𿬠ç¹ã®äž¡æ¹ããããããããåäœå¶éåã«ã¯ãæ·±å»ãªåè£ãšå éšæäºãã€ããŸãšãããšãèŠæããªããã°ãªããªããäŸãã°ãïŒãã¥ãŒã¹ããŒã°ã«å£ã£ãŠïŒãHIVãã®åé¢ã¯èšŒæãããŠããããHIVããšã€ãºãåŒãèµ·ããããã§ã¯ãªããšèãã人ã ããããäžæ¹ãïŒããŒã¹ã»ã°ã«ãŒãã«å£ã£ãŠïŒãHIVããå®å®ããç²åã§ããããšã¯èšŒæãããŠããªãïŒåé¢ã蚌æãããŠããªãïŒãšèãã人ã ããããã©ã¡ãã®ã¢ãããŒãããåäœå¶ãšã€ãºéåãã®äžã«äœçœ®ã¥ãããããããããªãããããããã®ã¢ãããŒãã¯ããšã€ãºïŒããã³ææè ïŒãžã®å¯ŸåŠã ãã§ãªãããŠã€ã«ã¹åŠåéã®èªèè«ã«ã€ããŠãå šãç°ãªãæŠç¥ã瀺åããŠãããããŒã¹ã»ã°ã«ãŒãã®ã¢ãããŒãã¯ãïŒã¬ãããŠã€ã«ã¹ã®åé¢ã«é¢ãããäŒçµ±çãªããã¹ããŒã«ã®èŠåãåŒçšããŠïŒHIVãŠã€ã«ã¹åŠã®èªèè«ãéå®éšçã«æ¹å€ãããšã€ãºã®å°éå®¶ã¯é žåã¹ãã¬ã¹ã«å¯Ÿæããæ²»çæ³ã詊éšçã«è©Šãã¹ãã ãšç€ºåããããã¥ãŒã¹ããŒã°ã®ã¢ãããŒãã¯ããHIVããŠã€ã«ã¹åŠã®èªèè«ã«é¢ããŠã¯ããã»ã©éæ¿ã§ã¯ãªãã£ããã®ã®ãHIVã«å¯Ÿããæ£çµ±çãªæã¬ãããŠã€ã«ã¹çæ³ã«ã¯æ ¹æ¬çã«å察ããŠããã
7. åäœå¶éåã«ãã£ãŠãšã€ãºæ²»çã¯é²æ©ããã®ã§ããããïŒåœ±é¿ã¯ãã£ãã®ã§ããããïŒçŸåšã®æ¹ãè¯ããªã£ãŠããã®ã§ããããããããšãæªããªã£ãŠããã®ã§ããããïŒ
æžèªç§åŠããŒã¿ããŒã¹ã®åŒçšæç®ã粟æ»ãããšããšã€ãºç°ç«¯éåãäž»æµã®ãšã€ãºç§åŠãæ²»çæ³ã«æ£åŒãªåœ±é¿ãäžããäºäŸã¯ã»ãšãã©ããããã¯å šããªãããšãããããããããªãããã®æå³ã§ããšã€ãºç°ç«¯éåã¯å€±æã ã£ããšå€æããããããããªããããããäž»æµæŽŸãç°ç«¯æŽŸã®ç ç©¶ããæ©æµãåãããšããææããããäŸãã°ãããŒã¹ã»ã°ã«ãŒãã®ãŠã§ããµã€ãã§ã¯ãé žåã¹ãã¬ã¹ã«é¢ãã圌ãã®ç ç©¶ãæé»ã®ãã¡ã«äž»æµæŽŸã«åœ±é¿ãäžãããšç€ºåããŠããã瀟äŒç§åŠè ããšã€ãºç§åŠç°ç«¯æŽŸã®ç ç©¶ãåŒçšããŠããããå€ãã®å Žåãäž»æµæŽŸã®ç«å ŽããåŒçšããŠããã
ãšã€ãºã«é¢ããç°è«ã¯ãäžè¬ã®äººã ïŒHIVææè ãå«ãïŒã«å€§ããªåœ±é¿ãäžããŠããå¯èœæ§ãããããªããªãããšã€ãºç°è«è ããçºããããæ§ã ãªèšèª¬ã¯ã質çç ç©¶ã®ãµã³ãã«ãéç§åŠçãªåºçç©ã«ãç»å Žããããã§ãããæ£è ãåŸæ¥ã®æ²»çæ³ã«çåãæ±ãå§ããåææ€åæš©ãè¡äœ¿ããŠãå®ååãããäž»æµã®å»çããé¢è±ããããã«ãªãã«ã€ãããšã€ãºç°è«ã®æ€é²ãæ±ãã声ãé«ãŸã£ãŠããã®ã¯ãã®ããã§ããã
ãŸããæŽå²çã«èŠãŠãããšã€ãºå察掟ã®éã«ã¯é£åž¯ã®æ¬ åŠãèŠãããã2006幎ãããŒã¹ã»ã°ã«ãŒãã®ã¡ã³ããŒ2åïŒãšã¬ãã»ãããããã¹ïŒãšã¬ãªããã¹ãšãŽã¡ã«ã»ã¿ãŒããŒïŒã¯ã3人ã®å¥³æ§ã«HIVãæ æã«æ§çã«ææããããšããŠåçºãããåŸã«æçœªå€æ±ºãåããã¢ã³ãã¬ã»ãã£ãã»ãã¬ã³ãžãŒã®2006幎ã®ãªãŒã¹ãã©ãªã¢ã§ã®è£å€ã§ãåŒè·åŽã®å°é家蚌人ãšããŠæ³çã«æç€ºãåãããæå€§ã®ãšã€ãºå察掟ã°ã«ãŒãããªã·ã³ãã³ã°ã»ãšã€ãºãã®ãªãŒããŒã§ããããããã»ã¯ããŠã¯ãåŒè·åŽã®åŒè·å£«ã«å¹²æžããã
ããŒã¹ã»ã°ã«ãŒãã®ã¡ã³ããŒ2人ã¯ãHIVãæ±ºããŠåé¢ããããã®ã§ã¯ãªãããšã瀺ãç ç©¶ã«åºã¥ããŠåŒè·ãæ åœããããæç€ºããããã¯ããŠã¯ããããããã¹ïŒãšã¬ãªããã¹ãšã¿ãŒããŒãåŒè·ããå€ããã¯ããŠãããä¿¡é Œæ§ãé«ãç¡çœªã®å¯èœæ§ãé«ããšèãããŠã€ã«ã¹æè·æŽŸã®å°é家蚌人ãåŒè·åŽã«ç«ãŠãããšãæãã§ãããšäŒããããŠãããã¯ããŠãåŒè·åŽã«ä»å ¥ããããšã§è£å€å®ãããŒã¹ã»ã°ã«ãŒãã解任ããããããã®ç¶æ³ã¯ãšã€ãºå察éåå ã§å€§ããªæ¿æ²»çæ³¢çŽãåŒãã ã
æè¿ã§ã¯ããšã€ãºå察掟ã ã£ã人ãå¿ ãããCOVIDå察掟ã ã£ãããã§ã¯ãªãããã®éããŸãç¶ãã§ããããå察掟ãå¥ã®å察掟ã«ãªãããã§ã¯ãããŸãããCOVIDã®ãåã¯ã¯ãã³æŽŸãã®å€ãã¯ãåãŠã€ã«ã¹æŽŸãã§ã¯ãããŸããã§ãããèåãªãšã€ãºå察掟ã®äžäººã¯ãCOVIDã®ãæ£äœãæŽããããšã䜿åœãšããå£äœã®çäºãåããªãããCOVIDã®ãã¯ã¯ãã³æ¥çš®ããåããããšãå ¬ã«èªããå ¬ã«ã¯æ£å察ã®ããšã䞻匵ããªãããç§åŠçã«ççŸããç«å Žã瀺ããŸããã
ãšã€ãºãšãã®å察éåããããç€ŸäŒæ¿æ²»çãªè«äºã¯ãéåžžã«è€éã ãå察掟å éšã§ãããç°è°ç³ãç«ãŠãšåè«ããããŠç倧ãªäºè£ãåè£ãçµ¶ããªãã
8. ããªãã¯ãšã€ãºç æ£ã§ãéœæ§åå¿ãåºãäººãæ»ã«è³ãéçšããã¥ãŒãã©ãŒïŒãã¹ã»ã«ãŠã³ã»ãªã³ã°ãªã©ããã®çŸå®ãç®ã®åœããã«ããŸãããæ²»çã®åã®äžã«äººã ã«äœããªãããŠãããã象城ãããããªãä»ã§ãå¿ã«æ®ã£ãŠããæ£è ãåºæ¥äºã¯ãããŸããïŒ
æŽå²çã«ãè€æ°ã®å䜵çãæ±ããé節ãªãšã€ãºæ£è ã¯ããäºåŸæ²èŠ³äž»çŸ©ããšããèšãããã®ãªãå»çäœå¶ã®äžã§æ²»çãããŠãããå€ãã®æ£è ã¯æ»äº¡ãããšäºæ³ãããçè·åž«ã¯å®éã®çççç¶æ ãæªåããåãç¹ã«äŸµè¥²çãªåŠçœ®ïŒæ°ç®¡æ¯é¡æ€æ»ãªã©ïŒãè¡ãéã«ã¯ãèçåŠçœ®ãè¡ããªãããã«æç€ºãããŠããã
æ»ã¯äºæãããäºæž¬ããããããŠå€ãã®å Žåãããããæ²èŠ³çãªäºåŸäºæž¬ã«ãã£ãŠåŒãèµ·ãããããšç§ã¯äž»åŒµãããã
ããäºäŸã§ã¯ããã¥ãŒã¢ã·ã¹ãã¹èºçãšèšºæãããæ£è ã«ããžã¢ã¢ã«ãã£ã³15mgãéèå æäžããããåŠæ¹ããïŒContinuum Magazine Vol 5 (1), p.24åç §ïŒãæ£è ã¯ãããã³ã«è¬ã«åå¿ãããåŒåžæ°ãå€ãã£ããããå»çããŒã ã¯æ°ç®¡æ¿ç®¡ãšäººå·¥åŒåžã®ããã«éäžæ²»ç宀ã«å ¥é¢ãããªãããšã決å®ããã
ïŒç§ã®çµéšã§ã¯ããã®ãããªåœãæãå¯èœæ§ã®ããæ²»çæ³ãå§ãããããšã€ãºæ£è ã¯ã»ãšãã©ããŸããã§ããããã£ãšããã³ããçŠã«ãããŠã¯ãããããæ²»çæ³ã¯äžå¿ èŠã«å®æœããããããæ»ã®çœ ãšåããŠããŸã£ãã®ã§ãããïŒ
æ åœçè·åž«ãšããŠãç§ã¯åŠæ¹ãããçšéã®æäžãæåŠããéåžžã®ããŒã©ã¹æäžãããé·ãæéããããŠ2.5mgãç®äžæäžããŸããããã®åŸãç§ã¯ãã®ç¹å®ã®åŠæ¹ç®ãæ¹æ¶ããŸããïŒãããŠåŸã«ãã®ããšã§æ²æåŠåãåããŸããïŒããããããã®éã«æçç©è³ªã®å€æŽãå¿ èŠãšãªããåŠæ¹ããããžã¢ã¢ã«ãã£ã³ã®éå°æäžããªãã£ããããæ£è ã¯å®éã«çãå»¶ã³ãŸãããæ°é±éåŸã圌ã¯éé¢ãããã®åŸ4幎éçããŸããããã®äºäŸã¯ããšã€ãºã«å¯Ÿããå»åŠçã®æ²èгè«ãããã«æ ¹æ·±ããæ»ãæ©ããå¯èœæ§ããã£ãããç§ãã¡å šå¡ã«ç€ºããŸããã
ãããããæ²»çæŠç¥ãã¯ãäºå®äžãå æ¬çãªã宿¥œæ»ããããã³ã«ã®äžåœ¢æ ã§ãã£ããå€ãã®æ£è ã®ã«ã«ãã«ã¯ãæ£è æ¬äººããã®å®¶æã«äºåã«éç¥ããããæ³çåæãåŸããããåã«ãäžçŽå»åž«ãæ£è ã®å»çèšé²ã®è¡šçŽã«é»ãç¹ãä»ãããšããã«ã©ãŒã³ãŒããçšããŠããèçæªçœ®æåŠããšæèšãããŠããã
ããã¯å°å ã®ç é¢ã§èµ·ãã£ãŠããããšã§ãããä»ã®ç é¢ã§ã¯ç°ãªã蚺çãã¿ãŒã³ãèŠãããŸãããããããç§ã®çµéšãããããšãåœæïŒ1987幎ïŒã¯ä»ã®ç é¢ãšç§ãå€åããŠããç é¢ãšã®éã§ãèšºçæ¹æ³ã«ããã»ã©å€§ããªéãã¯ãªãã£ãã®ã§ã¯ãªãããšæããŸãã
9. åäœå¶éåã«ã¯ããã¥ãŒã¹ããŒã°ãããŒã¹ã»ã°ã«ãŒããããªã¹ãšãã£ãåªç§ãªç§åŠè ãã¡ãããã«ãããããããã»ãšãã©ã®äººã¯åœŒãã®ããšãèããããšããªããåäœå¶æŽŸã¯ãã®åŸã©ããªã£ãã®ãããããŠããã¯COVID-19ãã³ãããã¯äžã«åäœå¶æŽŸã®å£°ãåãã圱é¿ãšã©ãã»ã©äŒŒãŠããã®ãïŒ
ãšã€ãºã«ç°è°ãå±ãã人ã ã¯ãäºã€ã®æŽŸé¥ã«åããããå°æ°ã®ç§åŠè ã¯ããŒã¹ã»ã°ã«ãŒãã«å ããããHIVãåé¢ç§åŠã«ç°è°ãå±ããããã¢ã³ã¿ããšãšã¬ãã®ç ç©¶ãå®å šã«æŽé²ããããã«å¿ èŠãªå®éšããã°ã©ã ã宿œããããã®è³éãå®éšå®€ã®å°éç¥èãžã®ã¢ã¯ã»ã¹ãéãããŠãããæ¯èŒçå€ãã®ç§åŠè ã¯ããŒã¿ãŒã»ãã¥ãŒã¹ããŒã°ã«å ãããã¢ã³ã¿ããšãšã¬ãã®HIVåââé¢ç§åŠã¯åãå ¥ãããã®ã®ããHIVãããšã€ãºãåŒãèµ·ãããšããäž»åŒµã«æ¿ããç°è°ãå±ããé¢é£ããå»è¬åä»å ¥ïŒãæã¬ãããŠã€ã«ã¹è¬ãïŒã®äœçšãåŠå®ããã
åæ§ã«ããããäºã€ã®æŽå²çãªæŽŸé¥çã¢ãããŒãã¯ããã®åŸãCOVIDãïŒãSARS-CoV-2ãã§ãç¹°ãè¿ãããããããã£ãŠããšã€ãºãšCOVIDã®äž¡æ¹ã«ãããæ¹å€çèªèè«ã®å察è ãã¡ã«èµ·ãã£ãããšã«ã¯ãè°è«ã®äœå°ã®ããé¡äŒŒæ§ããããšèšããã ããã
10ïŒãã¢ããªã«ã«ããããšã€ãºãã¯ãHIV察çå šäœã«ãšã£ãŠäŸç¶ãšããŠéèŠãªå«ççè«æ ã®äžã€ã§ããããªãã®ç ç©¶ãããã¢ããªã«ã«ããããšã€ãºã®èšºæã¯çŸå Žã§å®éã«äœãæå³ããã®ãããããŠããã®ç¹ãèžãŸããŠã仿¥ã®ã°ããŒãã«ãã«ã¹æ©æ§ïŒã²ã€ã財å£ãGAVIãWHOãªã©ïŒãã©ã®ããã«æããã¹ãã§ããããïŒ
HIV/AIDSã®ãã©ãã€ã ã«ãããŠã1980幎代ã®å»åŠæç®ã«ã¯ãHIVæäœæ€æ»ã®éç¹ç°æ§ïŒéææ§ããããŠã¢ããªã«ã«ããããããã®æ€æ»ã®é©ç𿹿³ã«ãã£ãŠéœæ§çµæã倿°çããããšã«é¢ããå ±åãæ°å€ããããŸãããæäœæ€æ»ãå¿ èŠãšããªãAIDSã®èšåºçå®çŸ©ïŒäŸãã°ãã³ã®å®çŸ©ïŒãæ£è ã«é©çšãããç«åŠçµ±èšäžãééããªãéœæ§çµæã倿°çãããšèããããŸããåç §æ€æ»ãæ¥åžžçã«å®æœãããŠããªãã£ãå¯èœæ§ãããããããéœæ§çµæã®å¢å ã«ã€ãªãã£ããšèããããŸãã
ããããçäŸæ¡å€§ã®ç°åžžã¯ãã¹ãŠãåŸæ¥ã®æ çµã¿ã®äžã§çºçãããå®çŸ©ãæ€æ»ã«ãã£ãŠå å«ãããéå¥èšºæã®ç¯å²ãåºãã£ãããããšã€ãºã®èšºæãå®éã«äœãæå³ããã®ããçè§£ããããšã¯å°é£ã ã£ãã1980幎代ã®åœéä¿å¥æ©é¢ã¯ãã¢ããªã«å€§éžã«å¯Ÿããè±æ€æ°å°åæ¿çã®äžç°ãšããŠãã¢ããªã«è«žåœã®å»è¬ååžå Žã西åŽè£œè¬ã«ã«ãã«ã«ããæŸåã®ããã«æ¯é ããããšãã¢ããªã«ã«ããããšã€ãºã«é¢ããããããå ±éãèªåŒµããã»ã³ã»ãŒã·ã§ãã«ã«å ±éããããåªããã
2000幎ã«ã¿ãã»ã ãã倧統é ãåã¢ããªã«ã®æ£çµ±çãªãšã€ãºç§åŠãå ¬ç¶ãšæ¹å€ããããšãã詊ã¿ã¯ãåœåã¯ç¡èŠãããŠãããã圌ããšã€ãºè«®åå§å¡äŒãçºè¡šããããŒã¿ãŒã»ãã¥ãŒã¹ããŒã°ãããããã»ã©ã¹ããã¯ãããŒãã€ã»ãã¢ãªãŒããšã¬ãã»ãããããã¹ïŒãšã¬ãªããã¹ããŽã¡ã«ã»ã¿ãŒããŒãªã©ãèåãªç°ç«¯ã®ãšã€ãºç§åŠè ãå§å¡ã«ä»»åœããããšã§ç¶æ³ã¯äžå€ããããã®æ¥é²çãªåãã¯ãäžçã®ä¿å¥æ©é¢ã«ãšã£ãŠæ¥ãã¹ãäºæ ãšãªã£ããã ããã®è¡åã¯ãCDCã®æ¥ãªä»å ¥ãæããCDCã¯ãã¬ã³ã»ã²ã€ã«çãã代衚å£ãåå£å Žã§æŽŸé£ããæ£çµ±æŽŸãšéº»è¬ã«ã«ãã«ã«æå©ã«ãªãããã«å¯©è°ã«åœ±é¿ãäžããããšããã
仿¥ã®ã°ããŒãã«ãªä¿å¥æ©é¢ã¯ããã®äžççãªæ¥èŸ±ããåŠã³ãååçãªå¯Ÿå¿ããèœåçãªããã³ãããã¯ãã®æ§ç¯ãžãšè»¢æãããããã¯ãäžççãªCOVIDãããã¯ã®åœ¢æãšå±éã«è²¢ç®ããç°è°ãå±ããããšããåœå®¶ãçŽæ¥çã«ææ¢ããã
11. HIVæ€æ»ã¯HIVèªäœã«å¯ŸããåŠ¥åœæ§ãæ€èšŒãããããšã¯äžåºŠããããŸãããæ·»ä»ææžã«ãåç §åºæºããªãããšãæèšãããŠããŸãããéé¢ããšã¯å ·äœçã«äœãæå³ããã®ããããŒã¹ã»ã°ã«ãŒãã瀺ããå 容ããããŠãããåãªãæè¡çãªåé¡ã§ã¯ãªããåºç€ã®åŽ©å£ãæå³ããçç±ã«ã€ããŠã詳ãã説æããŠããã ããŸããïŒ
以äžã¯ãã¬ãããŠã€ã«ã¹åé¢ãæ¬æ¥æå³ãããšããã«ã€ããŠã®ç§ã®èŠçŽã§ããã¬ãããŠã€ã«ã¹åé¢ã¯ãå®éšå®€ã§è¡ãäžé£ã®ç©ççããã³ååŠçæé ã§ãããŸããéºäŒç©è³ªãå«ããã现èãµã³ãã«ãçšæããŸããæ¬¡ã«ããµã³ãã«ãç²ç ããŠæ¶²äœç¶ã«ãããéããåŸãé å¿å颿©ã§é å¿åé¢ããŠç²Ÿè£œããŸããã¬ãããŠã€ã«ã¹ç²åã¯ãã·ã§ç³æº¶æ¶²äžã§1.16g/mlã®å¯åºŠãæã¡ãŸãããã®å¯åºŠã®ãããã§ããµã³ãã«ãé å¿å颿©ã§é å¿åé¢ããããšã§ããããã®ç²åãä»ã®çްèç©è³ªããåé¢ããããšãã§ããŸãããããã£ãŠãã·ã§ç³æº¶æ¶²äžã®1.16g/mlã®ãã³ãã¯ãã¬ãããŠã€ã«ã¹ç²åãå«ãŸããŠãããšèããããŠãããããé»åé¡åŸ®é¡æ€æ»ãçååŠåæã®ããã«æœåºãããŸãã
é»åé¡åŸ®é¡ãçšããŠãç²åãåäžã®ãµã€ãºãšåœ¢ç¶ã§ããããšã確èªããç©ççãªåäžæ§ãé©åã«æ€èšŒããŸããéºäŒåçµæã¯ã粟補ãããç²åããéºäŒåé åæ±ºå®æè¡ãçšããŠéºäŒç©è³ªãæœåºããåæããŸããçååŠçåæãè¡ããåŸãããéºäŒç©è³ªããã现èå éšïŒå å æ§ïŒç±æ¥ã®åè§£ç©è³ªã§ã¯ãªãããã现èå€éšïŒå€å æ§ïŒç±æ¥ã®ç©è³ªã§ããããšã確èªããŸãã
ããŒã¹ã»ã°ã«ãŒãã¯ã1980幎代åé ã«ã¢ã³ã¿ããšãšã¬ããHIVã®åé¢ã䞻匵ããéã«çºè¡šããè«æã«ãããŠãäžèšã®æé ãé©åã«èžãŸããŠããªãã£ãããšããéå®éšçãªæžé¢ã«ããæ¹å€ãéããŠæããã«ããŸããããããã£ãŠãããŒã¹ã»ã°ã«ãŒãã¯ã⊠HIV/AIDSã®å°éå®¶ã¯ãå€å çã«ç²åŸãããç¬èªã®ã¬ãããŠã€ã«ã¹ã§ããHIVã®ååšã蚌æããŠããªãããšäž»åŒµããŠããŸããhttps ://www.theperthgroup.com/whatargued.html
ã¬ãããŠã€ã«ã¹ã®åé¢ã«é¢ãããã詳现ãªèª¬æãšãã¢ã³ã¿ããšïŒã¬ãæ³ã«ããHIVåé¢ã®æ¬ é¥ã«é¢ããããŒã¹ã»ã°ã«ãŒãã®åæã«ã€ããŠã¯ã以äžã®è«æãåç §ããŠãã ãããPapadopulos-Eleopulos, E et al. HIV â A virus like no other. 2017幎7æ12æ¥ã«ããŒã¹ã»ã°ã«ãŒãã®ãŠã§ããµã€ãã«æ²èŒãwww.theperthgroup.com/HIV/ TPGVirusLikeNoOther.pdf
12. HIVãé©åã«åé¢ãããããšããªãã«ãããããããäœçŸäžäººãã®èšºæã®åºç€ãšãªã£ããšããã°ããŠã€ã«ã¹åŠãäžè¬çã«ã©ã®ããã«ãŠã€ã«ã¹ããçºèŠãããã®ãïŒçްèå¹é€ãPCRãã³ã³ã»ã³ãµã¹é åãªã©ïŒã«ã€ããŠãããã¯äœãç©èªã£ãŠããã®ã§ããããïŒ HIVã¯åãªãå¶ç¶ã®ç£ç©ãªã®ã§ããããããããšããã®æ¹æ³èªäœãæå³çã«ãã®ãããªçµæãçã¿åºããŠããã®ã§ããããïŒ
ãããã®çµæãçã¿åºããŠããã®ã¯ããŸãã«ãã®æ¹æ³èªäœãæ¬æ¥ã®èšèšã«åºã¥ããŠããããã§ãããããã®æ¹æ³ã¯ãéºäŒåé åæ±ºå®ã容æã«ãªããããªã¡ã©ãŒãŒé£éåå¿ãªã©ã®æè¡ã容æã«å°å ¥ã§ããããã«ãªã£ãããšã§ãé·å¹Žã«ããã£ãŠå®æœãããããªãããã€ãŠãªãã»ã©æ®åããŠããŸãããäž»æµã®åéããèŠãŠããHIVåé¢ã®äºäŸã¯ãçŸä»£ã®ãã€ãªãã¯ãããžãŒãããŠã€ã«ã¹åé¢ããšããæŠå¿µãåå®çŸ©ãããåŸæ¥åãã®å€å žçãªæ¹æ³ã®é©çšãããå¢å¹ ãããéºäŒåé åã®ã¿ãç¹å®ããŠå©çšããæ¹æ³ãžãšç§»è¡ãããŠããããšã瀺ããŠããŸãã
æãéèŠãªã®ã¯ããã¬ããªãã¯ã¹ãšã¬ã«ãã³ïŒ1996幎ã24ããŒãžïŒãã21äžçŽã«åããŠäŒçµ±çãªã³ããã®ååãæŽæ°ããããšè©Šã¿ãç»æçãªåºçç©ã®äžã§è¿°ã¹ãããšã§ããã
ãå¢å¹ ãããé åããå ¥æã§ããªãããããããã®æšå®ããã埮çç©ã®çç©åŠç圹å²ããããã¯ååšãã®ãã®ãããäžæã§ããããŸãã粟補ãããå®å šãªåŸ®çç©ãååšããªããããå®éšçã«çŸæ£ãåçŸããããšãã§ããªãïŒã³ããã®ç¬¬äžååïŒãã
ãã®ãããæ£çµ±æŽŸã®äž»æµæŽŸç§åŠè ã®éã§ããã埮çç©ãåé¢ããçŸä»£çãªæ¹æ³ã«çåãåãã声ãäžãã£ãŠããã
æšè«ãçè·¡ã¯ãå®å®ããç©è³ªçãªå®äœãšã¯ç°ãªãã
äœããååšããããååšããªããã®ã©ã¡ããã ã
åç §ïŒFredricks, DNãRelman, DA (1996) 埮çç©ç åäœã®é åã«åºã¥ãåå®ïŒã³ããã®ååã®åæ€èšãClinical Microbiological Reviewã9(1)ã18-33ãDOIïŒ10.1128/CMR.9.1.18